Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rule 8.3- Omega Diagnostics Group Plc

20 Oct 2009 11:52

RNS Number : 0842B
Henderson Global Investors Ltd
20 October 2009
 

FORM 8.3

DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE

(Rule 8.3 of the City Code on Takeovers and Mergers)

 

1. KEY INFORMATION

Name of person dealing (Note 1)

Henderson Global Investors Ltd

Company dealt in

Omega Diagnostics Group Plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

Ord 4p

Date of dealing

19/10/2009

 

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

 

(a)

Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

 

Long

Short

 

Number 

(%)

Number

(%)

(1) Relevant securities 

591,666

2.8675

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

591,666

2.8675

 

(b)

Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities 

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

 

(c) Rights to subscribe (Note 3)

 

Class of relevant security:

Details

3. DEALINGS (Note 4)

 

(a) Purchases and sales

 

Purchase/sale

Number of securities

Price per unit (Note 5)

Sale

25,000

0.38GBP

 

(b) Derivatives transactions (other than options)

 

Product name, e.g. CFD

Long/short (Note 6)

Number of securities (Note 7)

Price per unit (Note 5)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

 

Product name,e.g. call option 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price 

Type, e.g. American, European etc.

Expiry date

Option moneypaid/received per unit (Note 5) 

 

 

(ii) Exercising

 

Product name, e.g. call option

Number of securities 

Exercise price per unit (Note 5)

 

(d) Other dealings (including new securities) (Note 4)

 

Nature of transaction (Note 8) 

Details

Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

……………………………………………………………………

……………………………………………………………………

Is a Supplemental Form 8 attached? (Note 9) No

 

 

Date of disclosure

20/10/2009

Contact name

Gavin Dolding

Telephone number

020 7818 5217

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

Notes

The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

SUPPLEMENTAL FORM 8

 

 

DETAILS OF OPEN POSITIONS 

(This form should be attached to Form 8.1, Form 8.1(b)(ii) or Form 8.3, as appropriate)

 

 

 

 

OPEN POSITIONS (Note 1)

 

Product name,e.g. call option

 

Written or purchased

 

Number of securities to which the option or derivative relates

Exercise price (Note 2)

 

Type, e.g. American, European etc.

Expiry date

 

Notes

 

1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell should also be given on this form.

 

2. For all prices and other monetary amounts, the currency must be stated.

 

For details of the Code's dealing disclosure requirements, see Rule 8 and its Notes which can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETKGMZGGGMGLZM
Date   Source Headline
10th Apr 20187:00 amRNSStrategic Review of operations and Trading Update
12th Jan 201812:14 pmRNSHolding(s) in Company
21st Dec 20177:00 amRNSAllersys® CE-Mark
14th Dec 20177:01 amRNSCEO succession
14th Dec 20177:00 amRNSInterim results
29th Nov 20177:00 amRNSVISITECT® CD4 CE-Mark
1st Nov 20177:00 amRNSChange of Registered Office
23rd Oct 20177:00 amRNSTrading Update and Notice of Interim Results
18th Oct 20179:00 amRNSPDMR Participation in SAYE Scheme
16th Oct 20177:00 amRNSUS Supply Agreement
10th Oct 20177:00 amRNSHolding(s) in Company
5th Sep 20172:07 pmRNSExercise of Options and Total Voting Rights
29th Aug 201711:51 amRNSResult of AGM
18th Jul 201710:35 amRNSResult of General Meeting
6th Jul 201711:56 amRNSSale and leaseback of building owned by Omega GmbH
30th Jun 201712:13 pmRNSResult of Proposed Fundraising
30th Jun 20177:01 amRNSProposed Fundraising
30th Jun 20177:00 amRNSFinal Results
25th Apr 20177:00 amRNSTrading Update and Notice of Results
21st Apr 201712:41 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSVISITECT® Malaria CE-Mark & Indian FDA inspection
7th Mar 20178:45 amRNSHolding(s) in Company
27th Feb 201712:52 pmRNSHolding(s) in Company
27th Jan 20177:00 amRNSUpdate on discussions with IDS
11th Jan 20177:00 amRNSISO accreditation for manufacturing facility
29th Nov 20167:15 amRNSHardman Research: Food intolerance driving growth
24th Nov 20167:52 amRNSHolding(s) in Company
21st Nov 20167:00 amRNSHalf-year Report
31st Oct 20167:15 amRNSHardman Research: Diagnosing growth opportunities
17th Oct 20167:00 amRNSTrading Update and Notice of Interim Results
10th Aug 201612:22 pmRNSResult of AGM
2nd Aug 20167:00 amRNSR&D Grant Funding
4th Jul 20168:18 amRNSHolding(s) in Company
1st Jul 201611:48 amRNSHolding(s) in Company
27th Jun 20167:00 amRNSFinal Results
9th Jun 20169:07 amRNSHolding(s) in Company
21st Apr 20167:00 amRNSTrading Update & Notice of Results
8th Feb 20168:22 amRNSHolding(s) in Company
4th Dec 20154:25 pmRNSHolding(s) in Company
3rd Dec 201512:28 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSHalf Yearly Report
26th Oct 20157:00 amRNSTrading Update and Notice of Interim Results
30th Sep 20159:07 amRNSGrant of Options
7th Sep 20151:21 pmRNSResult of AGM
7th Jul 20157:00 amRNSFinal Results
5th Jun 201510:01 amRNSHolding(s) in Company
1st Jun 20157:00 amRNSDevelopment Update - Visitect® CD4 and Allergy
27th Apr 20157:00 amRNSBoard Appointment
15th Apr 20157:00 amRNSTrading update and Notice of Results
1st Dec 201410:37 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.